Covid-19 afflicts Eli Lilly’s share price and a KRAS drug gets tossed, but Jardiance win salves the wound as an antibody effort advances to PhII
Shares of Eli Lilly $LLY tumbled close to 2% on Thursday in a toxic reaction to its mixed revenue performance in the face of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
